Study of Descartes-30 in Acute Respiratory Distress Syndrome

a study on Acute Respiratory Distress Syndrome Respiratory Distress Syndrome COVID-19

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
estimated completion
Principal Investigator
by Richard A Lee, MD (uci)

Description

Summary

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Official Title

Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome

Keywords

Acute Respiratory Distress Syndrome Covid19 Respiratory Distress Syndrome Respiratory Distress Syndrome, Newborn Acute Lung Injury Syndrome Descartes 30

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients must be 18 years of age or older at the time of enrollment
  • Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS

You CAN'T join if...

  • Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA.
  • Patient is in moribund state with expected survival <24 hours.

Locations

  • University of California-Irvine accepting new patients
    Irvine California 92697 United States
  • University of Oklahoma Health Sciences Center accepting new patients
    Oklahoma City Oklahoma 73104 United States

Lead Scientist at University of California Health

  • Richard A Lee, MD (uci)
    Assistant Health Sciences Professor, Medicine, School of Medicine

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cartesian Therapeutics
ID
NCT04524962
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated